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ABSTRACT A factor with tumor necrosis factor (TNF)
activity produced by the LuKII human lymphoblastoid cell line
[designated TNF(LuKII)] was purified sequentially by using
controlled-pore glass, lentil lectin-Sepharose, and procion red
agarose chromatography, yielding TNF with a specific activity
of 1.5 x 107 units per mg of protein and an isoelectric point
of =6.7. Purified TNF(LuKII) fractionated by NaDod-
S04/PAGE under reducing as well as nonreducing conditions
was found to contain seven protein bands ofMr 80,000, 70,000,
43,000,25,000, 23,000, 21,000, and 19,000. The proteins ofMr
80,000 and 70,000 could not be dissociated into lower molecular
weight components. Peptide mapping analysis and immuno-
blotting analysis revealed that the seven protein bands in the
purified TNF(LuKII) preparations are related. After fraction-
ation of TNF(LuKII) by NaDodSO4/PAGE under reducing
conditions, TNF activity was recovered from the regions ofM,
70,000 and 19,000-25,000. Purified human TNF(LuKII) (i)
produces hemorrhagic necrosis of Meth A mouse sarcoma in
the standard in vivo mouse TNF assay; (ii) has the same pattern
of reactivity as mouse TNF (cytotoxic/cytostatic/no effect) on
a panel of human cancer cell lines; and (iii) has its anticellular
effect potentiated by interferon, also a feature of mouse TNF.
The presence of a tumor inhibitory factor in the sera of mice
infected with bacillus Calmette-Guerin (BCG) and subse-
quently injected with endotoxin was reported by Carswell et
al. (1). Sera from these mice cause necrosis and regression of
certain tumors in mice and have a cytotoxic effect on tumor
cells in vitro (1-5). By using similar methods, a factor with the
same in vivo and in vitro properties can be induced in rats (1)
and rabbits (1, 6, 7). The antitumor factor present in the sera
of animals sensitized to BCG or other immunopotentiating
agents, such as Corynebacterium parvum or Zymosan, and
then challenged with endotoxin has been termed tumor
necrosis factor (TNF). Biochemical studies have indicated
that serum TNV activity is associated with both high molec-
ular weight components (4, 8) and components in the Mr
range of 40,000 to 70,000 (3-5, 9, 10).
We have recently reported that human cell lines of hem-
atopoietic origin have the capacity to produce a factor with
TNF activity (11). The product of one of the lines (LuKII)
was chosen for detailed studies and, according to the follow-
ing criteria, TNF(LuKII) and mouse TNF have identical
properties: (i) mouse L cells made resistant to mouse TNF
are resistant to TNF(LuKII), and L cells made resistant to
TNF(LuKII) are resistant to mouse TNF; (ii) the anticellular
response of a panel of human cell lines to TNF(LuKII) or
mouse TNF is indistinguishable and can be potentiated in a
synergistic fashion by interferon; and (iii) TNF(LuKII)
causes hemorrhagic necrosis of Meth A sarcomas in the
standard in vivo TNF assay (11).
In the present study, we report a sequential chromato-
graphic procedure for the purification of TNF(LuKII) and
describe biochemical, serological, and biological character-
istics of purified TNF(LuKII).
MATERIALS AND METHODS
Production of TNF(LuKII). LuKII cells (8 x 105 cells per
ml) in RPMI 1640 medium containing 8% fetal calf serum
were incubated with 10 ng of mezerein per ml (L. C.
Services, Woburn, MA) for 48 hr. The cells were separated
by centrifugation, resuspended in fresh RPMI medium lack-
ing any protein supplement, and incubated for an additional
48 hr. Cells were removed by centrifugation, and the culture
media were used as the source of TNF(LuKII).
In Vitro TNF Assay. TNF assays were performed in 96-well
microtiter plaites. Serially diluted fractions were sterilized by
ultraviolet radiation and TNF-sensitive L cells were added to
each well at a density of 2 x 104 cells per well in 100 pl. After
incubation for 2 days at 370C, the plates were examined
microscopically and the percentage of dead cells was deter-
mined. The unitage of the sample was calculated as the
reciprocal of the highest dilution that killed 50% of the cells.
All TNF assays were run in parallel with a laboratory
standard and titers are expressed in laboratory units.
In Vivo TNF Assay. The standard Meth A sarcoma assay
was performed as described (11).
Monoclonal Antibody to Human TNF. BALB/c mice were
injected with 1600 units of TNF(LuKII), with a specific
activity of 1.5 x 107 units/mg. For the initial injection,
TNF(LuKII) was mixed with Freund's complete adjuvant
(1:1) and was injected subcutaneously. Subsequent injections
were given intraperitoneally in the absence of adjuvant.
Serum antibody to TNF(LuKII) was determined by an
ELISA with TNF(LuKII) bound to polystyrene plates. After
nine immunizations over a period of 7 months, the spleen of
one mouse with a high titer of TNF(LuKII) antibody was
removed and fused with cells of the P3U1 mouse plasma-
cytoma cell line. Resulting clones were screened for their
ability to bind TNF(LuKII) in ELISAs. A hybridoma (des-
ignated T1-18) producing antibody reactive with TNF-
(LuKII) was isolated and subcloned. Media from T1-18
hybridoma cultures served as a source of TNF(LuKII)
antibody.
Affinity Chromatography. Affinity chromatography proce-
dures were carried out at room temperature and column
fractions were collected into polypropylene tubes or bottles.
The column matrices used were controlled-pore glass 350
(Electro-Nucleonics, Fairfield, NJ), lentil lectin-Sepharose
Abbreviation: TNF, tumor necrosis factor.
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FIG. 1. (A) Controlled-pore glass column chromatography. LuKiI culture medium (8 liters) containing 200 units ofTNF activity per ml was
applied to a controlled-pore glass column (50 ml) equilibrated with phosphate-buffered saline (20 mM sodium phosphate, pH 7.0/0.15 M NaCl)
(PBS). The column was washed with the following buffers in sequence: PBS (75 ml); PBS containing 20% ethylene glycol (vol/vol) (E1) (225
ml); PBS (120 ml)/20 mM sodium phosphate, pH 7.0/1.15 M NaCl (E2) (175 ml); PBS (50 ml)/5 mM sodium phosphate, pH 6.8 (E3) (225 ml);
and 5 mM sodium phosphate, pH 6.8/5% triethylamine (vol/vol) (E4) (150 ml). Eluted fractions were collected in polypropylene bottles. The
material eluted with the E4 buffer was collected in 50-ml aliquots. (B) Lentil lectin Sepharose column chromatography. Partially purified
TNF(LuKII) (150 ml) eluted from the controlled-pore glass column was loaded onto a lentil lectin-Sepharose column (10 ml) equilibrated with
PBS. The column was washed sequentially with PBS (40 ml), PBS/1 M NaCl (El) (24 ml), and PBS/i M NaCl/0.2 M methyl-ca-D-mannoside
(E2) (60 ml). The material eluted with the methyl-a-D-mannoside-containing buffer was collected in 10-ml aliquots. (C) Procion red agarose
column chromatography. Partially purified TNF(LuKII) (60 ml) eluted from the lentil lectin-column was diluted 1:1 with PBS and loaded onto
a procion red agarose column (4 ml) equilibrated with 20 mM sodium phosphate, pH 6.8/0.65 M NaCl (PBS/0.5 M NaCl). The column was washed
with the following buffers in sequence: PBS/0.5 M NaCl (El) (30 ml); PBS/1 M NaCl (E2) (8 ml); PBS (8 ml); PBS/50% ethylene glycol (vol/vol)
(E3) (8 ml); PBS (8 ml); 0.1 M Tris-HCl, pH 9.4/0.1 M NaCl (E4) (8 ml); and 0.1 M Tris HCl, pH 9.4/0.1 M arginine (E5) (24 ml). The material
eluted with the 0.1 M Tris HCl, pH 9.4/0.1 M arginine buffer was collected in 4-ml aliquots.
(Pharmacia), and procion red agarose (Bethesda Research
Laboratories).
Protein Determinations. Protein determinations were car-
ried out with the Bio-Rad dye reagent (I3io-Rad) using bovine
serum albumin as a standard.
Radioiodination of TNF(LuKII). TNF(LuKII) was labeled
with 125I using 1,3,4,6-tetrachloro-3a,6a-diphenylglycouril
(Iodo-Gen, Pierce). Polypropylene tubes were coated with 100
tug of lodo-Gen (dissolved in chloroform) by evaporation of the
solvent. A 2-ml sample of TNF(LuKII) (50,000 units/ml) with
a specific activity of 1.5 x 107 units per mg of protein was
incubated for 25 min at room temperature in an lodo-Gen-
coated tube containing 2 mCi of 125I (1 Ci = 37 GBq). The
labeled protein was then separated from the unbound 1251 by
using a Pa column (Bio-Rad). equilibrated with phosphate-
buffered saline containing 50 ug of cytochrome c per ml. The
iodinated material eluted in the void volume of the column was
divided into aliquots and stored at -80TC.
NaDodS04/PAGE. NaDodSO4/PAGE was carried out in
18-cm slab gels according to published methods (12).
Isoelectrofocusing. Isoelectrofocusing was performed by
using Ampholine Pagplates (pH 3.5-9.5) (LKB). The gels
were run at 30W for 1.5 hr, at which time the pH gradient was
measured and the gel was sliced into 18 equal pieces. The gel
fractions were incubated for 18 hr in Eagle's minimum
essential medium (ME medium) containing 10% fetal calf
serum and fractions were assayed for TNF in vitro.
Peptide Mapping Analysis. A 251I-labeled preparation of pu-
rified TNF(LuKII) was fractionated by NaDodSO4/PAGE and
individual bands localized by autoradiography were cut from
the gel and treated with L-1-tosylamido-2-phenylethyl
chloromethyl ketone-treated trypsin or N-a-tosyllysine
chloromethyl ketone-treated chymotrypsin. Digested fractions
were analyzed according to the methods of Elder et al. (13).
Immunoblotting Analysis. Immunoblotting was performed
essentially as described (14). Briefly, preparations of purified
TNF(LuKII) were transferred to nitrocellulose paper over-
night at 100 mA. After incubation of the nitrocellulose paper
in buffer containing bovine serum albumin, the paper was
exposed for 2 hr to 40 ml ofT1-18 antibody-containing culture
medium. The nitrocellulose paper was then washed exten-
sively and incubated overnight in 10 mM Tris-HCl, pH
7.4/0.9% NaCI/5% bovine serum albumin/'251-labeled rabbit
anti-mouse IgG. The nitrocellulose paper was further washed
and exposed to x-ray film.
RESULTS
Purification of TNK(LuKII). Controlled-pore glass beads
bound all TNF activity from LuKII culture fluids. After
washing with several buffers in sequence, TNF activity was
Table 1. Purification of TNF(LuKII)
Load Recovery
Specific Specific
activity, activity, % -Fold
Column Units units/mg Units units/mg recovery purification
Controlled-pore glass 1.6 x 106 5.3 x 103 9.6 x 10 3.8 x 105 60 72
Lentil lectin-Sepharose 9.6 x 105 3.8 x 105 6.3 x 105 1.3 x 106 39 245
Procion red agarose 6.3 X 105 1 X 106 6.3 x 105 1.5 x 107 39 2830
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eluted with a 5 mM sodium phosphate buffer (pH 6.8)
containing 5% triethylamine (Fig. lA). The eluted TNF was
then applied to a lentil lectin-Sepharose column, which was
washed first with phosphate-buffered saline and then with
0.02 M sodium phosphate buffer (pH 6.8) containing 1.15 M
NaCl (buffer A). TNF activity was eluted from this column
with buffer A containing 0.2 M methyl-a-D-mannoside (Fig.
111). All TNF activity bound to the lentil lectin-Sepharose
column and 39% of the activity was recovered in the
methyl-a-D-mannoside-containing buffer. (Further washing
of the column with buffer containing 50% ethylene glycol
elutes only a small amount of additional TNF activity.) TNF
from the lentil lectin column was then diluted 1:1 with
phosphate-buffered saline and loaded onto a procion red
agarose column. The column was washed sequentially with
several buffers that remove protein having no TNF activity.
The column was then washed with 0.1 M Tris-HOl, pH
9.4/0.1 M arginine. TNF activity was eluted with this buffer,
yielding TNF with a specific activity of 1.5 x i0' units per mg
of protein. Table 1 summarizes the purification scheme for
TNF(LuKII) with specific activities of the resulting fractions.
Biochemical Characterization of Purified TNF(LuKII).
Isoelectric focusing of purified TNF(LuKII) indicates an
isoelectric point of ==6.7 (Fig. 2). "'I1-labeled TNF(LuKII) with
a specific activity of 1.5 x 10 units per mg of protein was
analyzed by NaDodSO4/PAGE and found to contain seven
protein bands with Mr values of 80,000, 70,000, 43,000, 25,000,
23,000, 21,000, and 19,000 (Fig. 3). The same seven protein
bands were observed when nonlabeled purified TNF(LuKII)
was fractionated by NaDodSO4/PAGE and examined by silver
staining. The proteins ofMr 80,000 and 70,000 were eluted from
the gels and reanalyzed by NaDodSO4/PAGE. They migrated
once again to the Mr 70,000-80,000 region, and no lower
molecular weight components were observed. In further exper-
iments, purified TNF(LuKII) was boiled in NaDodSO4, urea,
and 2-mercaptoethanol, and the same characteristic seven
bands were found.
To determine which bands in TNF(LuKII) showed TNF
activity, parallel samples of purified TNF(LuKII), one 125i1
labeled and -one unlabeled, were treated with 0.1%
NaDodSO4/0. 1 M 2-mercaptoethanol and fractionated by
NaDodSO4/PAGE. After electrophoresis, the lane contain-
ing the unlabeled material was cut into 4.'4-mm slices and theproteins were eluted from each slice by overnight incubation
at 40C in ME medium containing fetal calf serum. The parallel
lane containing 1251I-labeled TNF(LuKII) was dried immedi-
ately after electrophoresis and protein bands were located by
autoradiography. As seen in Fig. 4, TNF activity was recov-
ered from the gel at Mr values of 70,000 and 19,000-25,000,
corresponding to I25-labeled protein bands at these posi-
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FIG. 2. Isoelectrofocusing of TNF(LuKII). A 60-1.d sample of
purified TNF(LuKII) containing 1500 units was applied to an
ampholine gel (pH 3.5-9.5).
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FIG. 3. NaDodSO4/PAGE of puri-
fled I'll-labeled TNF(LuKII). TNF(Lu-
K11) was iodinated and fractionated by
NaDodSO4/PAGE. Autoradiographs
were developed for 18 hr (lane 1) and 0.5
hr (lane 2). The following proteins pro-
vided Mr markers: myosin (Mr, 200,000),
13-galactosidase (Mr, 130,000), phospho-
rylase b (Mr, 94,000), bovine serum albu-
min (Mr, 67,000), ovalbumin (Mr,
43,000), a-chymotrypsinogen (Mr,
25,700), /3-lactoglobulin (Mr, 18,400),
lysozyme (Mr, 14,300), and cytochrome
c (Mr, 12,300).
tions. TNF(LuKII) samples that were not exposed to 2-
mercaptoethanol before NaDodSO4/PAGE also showed
TNF activity at Mr values of 70,000 and 19,000-25,000.
To examine the relationships among the various protein
bands in purified TNF(LuKII) preparations, two-dimensional
chymotryptic and tryptic peptide mapping analyses were per-
formed. As seen in Fig. 5a, the chymotryptic peptide maps
demonstrate that the proteins of Mr 43,000, 25,000, 23,000,
21,000, and 19,000 are related and the proteins ofMr 80,000 and
70,000 are related. To examine the relationship of the larger
molecular weight proteins to the smaller proteins, chymotryptic
digests of the Mr 70,000 and 25,000 proteins containing equal
amounts of radioactivity were mixed and analyzed. As seen in
Fig. 5b, three of the fragments (termed A, B, and C) generated
by digestion of the Mr 25,000 protein migrate to the same
position as three fragments generated by digestion of the Mr
70,000 protein. A similar analysis was carried out using trypsin
as the proteolytic enzyme. The results also indicate that the
seven distinct forms are closely related.
Further evidence for the relationships among the various
proteins in purified TNF(LuKII) comes from immunoblotting
analysis with Tl-18 monoclonal antibody to TNF(LuKII).
Fig. 6 shows that the antibody reacts with the Mr 43,000 and
the Mr 19,000-25,000 components.
Biological Characteristics of Purified TNF(LuKII). Limulus
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FIG. 4. Recovery of TNF activity after NaDodSO4/PAGE frac-
tionation of TNF(LuKII). A sample of TNF(LuKII) containing 6000
units adjusted to contain 0.1% NaDodSO4 and 0.1 M 2-mercapto-
ethanol was applied to a 12% polyacrylamide gel. After electropho-
resis, the gel was sliced and activity was eluted and assayed. In an
adjacent lane, I'll-labeled TNF(LuK1I) was fractionated and auto-
radiographed to determine the molecular weight of the TNF(LuKII)
active fractions.
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tests of purified TNF(LuKII) indicate 25 ng of endotoxin per
nil. TNF(LuKII) causes hemorrhagic necrosis of Meth A
sarcoma after intratumoral or intravenous injection and total
tumor regression has been observed in some treated mice.
L-cell lines made resistant to mouse TNF or to partially
purified TNF(LuKII) are resistant to purified TNF(LuKII).
With the panel ofhuman cell lines studied by Williamson and
coworkers (11), purified TNF(LuKII) showed the same
pattern of reactivity (cytotoxic/cytostatic/no effect) as
mouse TNF and partially purified TNF(LuKII). In addition,
purified TNF(LuKII) and interferon showed synergistic
cytotoxic activity for human tumor cells, similar to what has
FIG. 5. Chymotryptic peptide mapping of 12"I-la-
beled proteins in purified TNF(LuKII).. 125I-abeled
TNF(LuKII) was fractionated on NaDodSO4/PAGE
and individual protein bands present in gel slices were
incubated overnight in the presence of 50 ,ug of N-a-
tosyllysine chloromethyl ketone-treated chymotrypsin
per ml. The individual gel slices were then washed with
water and samples (10,000 cpm) ofeach were lyophilized
to dryness. These samples were dissolved in a buffer
containing formic acid and acetic acid and were applied
to cellulose precoated glass TLC plates at the origin (x).
Electrophoresis (E) was performed from right to left,
followed by ascending chromatography in a buffer
containing butanol, pyridine, and acetic acid. Autora-
diographs of the chymotryptic maps of the Mr 80,000,
70,000, 43,000, 25,000, 23,000, 21,000, and 19,000 pro-
teins are presented (a); (b) chymotryptic maps of the Mr
25,000 and 70,000 and a mixture of the Mr 25,000 and
70,000 proteins.
previously been reported for partially purified TNF(LuKII)
and mouse TNF (12).
DISCUSSION
We have recently described the production, characterization,
and biological properties of a human factor with TNF activity
from the LuKII lymphoblastoid cell line (11). The further
purification and characterization of this factor, designated
TNF(LuKII), is the subject of this report. A protocol for the
purification of TNF(LuKII) has been developed that yields
both good recoveries ofTNF and material with high specific
activity. This purification protocol allows active fractions
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Mr x 10-3
43 -
' FIG. 6. Immunoblotting analysis of TNF-
(LuKI1) with T1-18 mouse monoclonal anti-
19-25 body. A sample of TNF(LuKII) containing
10,000 units was fractionated by NaDod-
S04/PAGE. Fractionated proteins were trans-
ferred to a nitrocellulose membrane and pro-
cessed as described.
eluted from one column to be applied either directly or after
dilution onto the next column, thereby eliminating any need
for dialysis and thus avoiding the losses associated with
dialysis. TNF(LuKII) has a Mr of 70,000 by gel filtration
under nonreducing conditions and an isoelectric point of 6.7.
Examination of purified TNF(LuKII) by NaDodSO4/PAGE
under reducing as well as nonreducing conditions revealed
the presence of seven protein bands ranging from Mr 19,000
to 80,000. The Mr 80,000 and 70,000 proteins could not be
dissociated into smaller molecular weight components even
after boiling in NaDodSO4/2-mercaptoethanol/urea. Frac-
tions from NaDodSO4/PAGE were assayed for TNF activity
and proteins in the Mr 70,000 and 19,000-25,000 region had
TNF activity. Using peptide mapping analysis, we found that
the seven proteins present in purified TNF(LuKII) were
related. Immunoblotting analysis with monoclonal antibody
to TNF(LuKII) showed shared determinants on the Mr
43,000 and 19,000-25,000 proteins. Antibody did not react
with the higher molecular weight forms, even though these
have been shown to be related to the Mr 43,000 and lower
molecular weight components. This could be due to the
inaccessibility of the determinant on the Mr 70,000 and 80,000
species. Thus, our analysis indicates that there are a number
of structurally related proteins in purified TNF(LuKII) and
that TNF activity is associated with nondissociable high
molecular weight and low molecular weight forms. We
conclude that the seven proteins in our purified TNF(LuKII)
are either the products of related genes or products DCof a
single gene that undergoes extensive processing.
TNF(LuKII) has the full range of biological activities
associated with mouse TNF. It produces hemorrhagic ne-
crosis of Meth A sarcoma in the standard TNF assay and
cannot be distinguished from mouse TNF in its pattern of
reactivity on a large panel of human cancer cell lines. In
addition, L cells made resistant to mouse TNF are resistant
to TNF(LuKII), and cells made resistant to TNF(LuKII) are
resistant to mouse TNF. Recent work has indicated that there
are surface receptors for TNF on TNF-sensitive cells (un-
published data). Competitive binding studies showed that
mouse TNF and TNF(LuKII) compete for the same receptor.
The relationship between TNF(LuKII) and lymphotoxin
(15, 16) is unclear. While they share certain properties, such
as their ability to kill mouse L cells, their affinity for lentil
lectin, their multiple forms, and, in some cases, their cellular
origin, they differ in certain biochemical properties. Ag-
garwal and coworkers (17, 18) have observed that lympho-
toxin from the RPMI 1788 lymphoblastoid cell line has a Mr
value of 25,000 and 20,000 under reducing conditions, where-
as TNF(LuKII) exists in several molecular weight forms,
some of which do not dissociate under reducing conditions.
Granger et al. (15) have also reported that species of
lymphotoxin exist in higher molecular weight forms. It seems
likely that there is a family of cytotoxic factors with TNF
activity and that lymphotoxin and TNF(LuKII) are members
of this family. This would be comparable to the interferon
system in which there are three major species, all having
antiviral activities, but each being coded for by a different
gene with varying degrees of homology. As in the interferon
field, the cloning offactors with TNF activity will provide the
basis for distinguishing various molecules of this family. The
recent cloning of human TNF (19-21) and human lympho-
toxin (22) has clarified the relationship between these two
molecules. Recombinant TNF and lymphotoxin are distinct
molecules of Mr 17,000 and 18,600 that share considerable
sequence homology. Both kill L cells and have tumor
necrosis activity. In light of the observation that TNF(LuKII)
exists in higher molecular weight forms, it seems unlikely that
all forms of TNF have been cloned.
This research was supported in part by grants from the National
Cancer Institute (CA-38661 and CA-08748).
1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore,
N. & Williamson, B. (1975) Proc. Natl. Acad. Sci. USA 72,
3666-3670.
2. Helson, L., Green, S., Carswell, E. A. & Old, L. J. (1975)
Nature (London) 258, 731-732.
3. Mannel, D. N., Meltzer, M. S. & Mergenhagen, S. E. (1980)
Infect. Immun. 28, 204-211.
4. Kull, F. C. & Cuatrecasas, P. (1981) J. Immunol. 126,
1279-1283.
5. Haranaka, K. & Satomi, N. (1981) Jpn. J. Exp. Med. 51,
191-194.
6. Matthews, N. & Watkins, J. F. (1978) Br. J. Cancer 38,
302-309.
7. Ostrove, J. M. & Gifford, G. E. (1979) Proc. Soc. Exp. Biol.
Med. 160, 354-358.
8. Green, S., Dobrjansky, A., Carswell, E. A., Kassel, R. L.,
Old, L. J., Fiore, N. & Schwartz, M. K. (1976) Proc. Natl.
Acad. Sci. USA 73, 381-385.
9. Matthews, N., Ryley, H. C. & Neale, M. L. (1980) Br. J.
Cancer 42, 416-422.
10. Ruff, M. R. & Gifford, G. E. (1980) J. Immunol. 125,
1671-1677.
11. Williamson, B. D., Carswell, E. A., Rubin, B. Y.,
Prendergast, J. S. & Old, L. J. (1983) Proc. Natl. Acad. Sci.
USA 80, 5397-5401.
12. Laemmli, U. K. (1970) Nature (London) 227, 680-685.
13. Elder, J. H., Jensen, F. C., Bryant, M. L. & Lerner, R. A.
(1977) Nature (London) 267, 23-28.
14. Burnette, W. N. (1981) Anal. Biochem. 112, 195-203.
15. Granger, G. A., Yamamoto, R. S., Fair, D. S. & Hiserodt,
J. C. (1978) Cell. Immunol. 38, 388-402.
16. Rosenau, W. (1981) Int. J. Immunopharmacol. 3, 1-8.
17. Aggarwal, B. B., Moffat, B. & Harkins, R. N. (1984) J. Biol.
Chem. 259, 686-691.
18. Aggarwal, B. B., Henzel, W. J., Moffat, B., Kohr, W. J. &
Harkins, R. N. (1985) J. Biol. Chem. 260, 2334-2344.
19. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H.,
Derynck, R., Palladino, M. A., Kohr, W. J., Aggarwal, B. B.
& Goeddel, D. V. (1984) Nature (London) 312, 724-729.
20. Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W. & Wallace,
R. B. (1985) Nature (London) 313, 803-806.
21. Wang, A. M., Creasey, A. A., Ladner, M. B., Lin, L. S.,
Strickler, J., Van Arsdell, J. N., Yamamoto, R. & Mark, D. F.
(1985) Science 228, 149-154.
22. Gray, P. W., Aggarwal, B. B., Benton, C. V., Bringman,
T. S., Henzel, W. J., Jarrett, J. A., Leung, D. W., Moffat, B.,
Ng, P., Svedersky, L. P., Palladino, M. A. & Nedwin, G. E.
(1984) Nature (London) 312, 721-724.
Immunology: Rubin et al.
